Treasury Secretary Bessent announces tariff relief on coffee, fruits
Investing.com - BTIG has lowered its price target on Xtant Medical (NYSE:XTNT) to $1.50 from $2.00 while maintaining a Buy rating following the company’s third-quarter 2025 results. Currently trading at $0.76, Xtant shares sit significantly below both BTIG’s target and the analyst consensus high target of $2.00, despite showing a strong YTD price return of 70.7%.
Xtant Medical reported revenue of $33.3 million, representing 19.0% year-over-year growth, slightly exceeding both BTIG and consensus estimates of $32.6 million and $32.7 million. The company posted earnings per share of $0.01, with license revenue of $5.5 million contributing significantly to the results. InvestingPro data shows Xtant’s revenue growth is consistent with its 5-year CAGR of 13%, with analysts expecting 14% growth for fiscal year 2025.
The company’s Orthobiologics segment grew 3.4% year-over-year, while Spinal Implants declined 6.5%, aligning with Xtant’s strategic focus on its Orthobiologics business. Gross margins reached approximately 66.1%, improving 770 basis points year-over-year and exceeding expectations. This represents a significant improvement over the 60.2% gross profit margin reported for the last twelve months.
Xtant Medical generated adjusted EBITDA of $4.5 million and improved its cash flow from operations. The company maintained its fiscal year 2025 guidance at $131 million to $135 million, representing 11% to 15% year-over-year organic growth. This aligns with InvestingPro Tips indicating that net income is expected to grow this year, with analysts predicting the company will be profitable in 2025 after posting losses in recent quarters.
BTIG noted that Xtant’s current cash position, combined with proceeds from a recent asset sale, positions the company to be self-sustainable going forward, with expectations for high single-digit growth in fiscal year 2026 and beyond as new products launch and investments in commercial operations continue. InvestingPro data confirms Xtant’s strong liquidity with a current ratio of 2.47, indicating liquid assets exceed short-term obligations. Want deeper insights? InvestingPro offers 8 additional ProTips and a comprehensive Research Report for Xtant Medical, one of 1,400+ US equities covered with in-depth analysis.
In other recent news, Xtant Medical Holdings Inc. reported its third-quarter 2025 earnings, surprising analysts with an earnings per share of $0.01. This result surpassed the anticipated loss of $0.01 per share. Additionally, the company reported revenue of $33.3 million, exceeding the forecasted $32.7 million and marking a 19% increase compared to the previous year. These results indicate a notable turnaround for Xtant Medical. The earnings and revenue figures were among the key highlights that caught investors’ attention. This positive financial performance has been a significant development for the company. Analysts had expected different results, making the actual performance noteworthy. The company’s ability to exceed expectations in both earnings and revenue is a significant update for stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.